The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients

Tuberculosis

Volumn 94, Issue 3, 2014, Pages 299-305

  Zaverucha Do Valle, Camila ^a   Monteiro, Sérgio P ^b   El Jaick, Kênia B ^a,c   Rosadas, Leonardo A ^a   Costa, Marli J M ^a   Quintana, Marcel S B ^a   De Castro, Liane ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

Author keywords

Anti tuberculosis drug; Cigarette smoking; Hepatotoxicity; Liver enzymes

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; CYTOCHROME P450 3A; NAT2 PROTEIN, HUMAN; TUBERCULOSTATIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYP2E1 GENE; CYP3A4 GENE; DRUG ACETYLATION; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NAT2 GENE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; TOXIC HEPATITIS; TUBERCULOSIS; CASE CONTROL STUDY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; DRUG-INDUCED LIVER INJURY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TUBERCULOSIS;

EID: 84900820919     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2014.03.006     Document Type: Article

References (39)

1. D. Yee, C. Valiquette, M. Pelletier, I. Parisien, I. Rocher, and D. Menzies Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis Am J Respir Crit Care Med 167 2003 1472 1477
2. A.M. Lee, J.Z. Mennone, R.C. Jones, and W.S. Paul Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics Int J Tuberc Lung Dis 6 2002 995 1000
3. J.G. Chamorro, J.P. Castagnino, R.M. Musella, M. Nogueras, F.M. Aranda, A. Frias, M. Visca, O. Aidar, S. Perés, and G.F. Gabriela F de Larrañaga Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs J Gastroenterol Hepatol 28 2013 323 328
4. R. Singla, S.K. Sharma, A. Mohan, G. Makharia, V. Sreenivas, B. Jha, S. Kumar, P. Sarda, and S. Singh Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity Indian J Med Res 132 2010 81 86
5. S.K. Sharma, A. Balamurugan, P.K. Saha, R.M. Pandey, and N.K. Mehra Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment Am J Respir Crit Care Med 166 2002 916 919
6. A. Fernandez-Villar, B. Sopena, J. Fernandez-Villar, R. Vazquez-Gallardo, F. Ulloa, V. Leiro, M. Mosteiro, and L. Piñeiro The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity Int J Tuberc Lung Dis 8 2004 1499 1505
7. J.R. Tost, R. Vidal, J. Cayla, D. Diaz-Cabanela, A. Jimenez, and J.M. Broquetas Severe hepatotoxicity due to anti-tuberculosis drugs in Spain Int J Tuberc Lung Dis 9 2005 534 540
8. V. Ramappa, and G.P. Aithal Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management J Clin Exp Hepatol 3 2013 37 49
9. C.Y. Chiang, K. Slama, and D.A. Enarson Associations between tobacco and tuberculosis Int J Tuberc Lung Dis 11 2007 258 262
10. S. Keshavjee, I.Y. Gelmanova, S.S. Shin, S.P. Mishustin, Y.G. Andreev, S. Atwood, J.J. Furin, and A. Miller Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome Int J Tuberc Lung Dis 16 2012 596 603
11. L.A. Kroon Drug interactions with smoking Am J Syst Pharm 64 2007 1917 1921
12. A. Tostmann, M.J. Boeree, R.E. Aarnoutse, W.C. de Lange, A.J. van der Ven, and R. Dekhuijzen Antituberculosis drug-induced hepatotoxicity: concise up-to-date review J Gastroenterol Hepatol 23 2008 192 202
13. J.R. Mitchell, U.P. Thorgeirsson, M. Black, J.A. Timbrell, W.R. Snodgrass, W.Z. Potter, H.R. Jollow, and H.R. Keiser Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites Clin Pharmacol Ther 18 1975 70 79
14. T. Yamamoto, T. Suou, and C. Hirayama Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype Hepatology 6 1986 295 298
15. V. Leiro-Fernandez, D. Valverde, R. Vazquez-Gallardo, M. Botana-Rial, L. Constenla, J.A. Agundez, and A. Fernández-Villar N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians Int J Tuberc Lung Dis 15 2011 1403 1408
16. N.P. Santos, S.M. Callegari-Jacques, A.K. Ribeiro Dos Santos, C.A. Silva, A.C. Vallinoto, D.C. Fernandes, D.C. de Carvalho, S.E. Santos, and M.H. Hutz N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients Int J Tuberc Lung Dis 17 2013 499 504
17. V.H. Gupta, D.N. Amarapurkar, M. Singh, P. Sasi, J.M. Joshi, R. Baijal, P.H. Ramegowda, A.D. Amarapurkar, K. Joshi, and P.P. Wangikar Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India J Gastroenterol Hepatol 28 2013 1368 1374
18. P.Y. Wang, S.Y. Xie, Q. Hao, C. Zhang, and B.F. Jiang NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis Int J Tuberc Lung Dis 16 2012 589 595
19. H.R. An, X.Q. Wu, Z.Y. Wang, J.X. Zhang, and Y. Liang NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients Clin Exp Pharmacol Physiol 39 2012 535 543
20. Y.S. Huang, H.D. Chern, W.J. Su, J.C. Wu, S.C. Chang, C.H. Chiang, F.Y. Chang, and S.D. Lee Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis Hepatology 37 2003 924 930
21. A.L. Jeovanio-Silva, T.P. Monteiro, K.B. El-Jaick, P.E. do Brasil, V.C. Rolla, and L. de Castro Unique CYP3A4 genetic variant in Brazilian tuberculosis patients with/without HIV Mol Med Rep 5 2012 153 161
22. T.D. Otto, E.A. Vasconcellos, L.H. Gomes, A.S. Moreira, W.M. Degrave, L. Mendonca-Lima, and M. Alves-Ferreira ChromaPipe: a pipeline for analysis, quality control and management for a DNA sequencing facility Genet Mol Res 7 2008 861 871
23. K.J. Rothman, and S. Greenland Modern epidemiology 2nd ed. 1998 Lippincott Williams & Wilkins Philadelphia, PA
24. P. McCullagh, and J.A. Nelder Generalized linear models 2nd ed. 1989 Chapman & Hall/CRC London
25. Team RDC R: a language and environment for statistical computing 2012 R Foundation for Statistical Computing Vienna, Austria
26. Y.S. Huang, H.D. Chern, W.J. Su, J.C. Wu, S.L. Lai, S.Y. Yang, F.Y. Chang, and S.D. Lee Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis Hepatology 35 2002 883 889
27. M. Ohno, I. Yamaguchi, I. Yamamoto, T. Fukuda, S. Yokota, R. Maekura, M. Ito, Y. Yamamoto, T. Ogura, K. Maeda, K. Komuta, T. Igarashi, and J. Azuma Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity Int J Tuberc Lung Dis 4 2000 256 261
28. J.A. Timbrell, J.R. Mitchell, W.R. Snodgrass, and S.D. Nelson Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo J Pharmacol Exp Ther 213 1980 364 369
29. M.D. Scales, and J.A. Timbrell Studies on hydrazine hepatotoxicity. 1. Pathological findings J Toxicol Environ Health 10 1982 941 953
30. T. Wang, H.T. Yu, W. Wang, Y.Y. Pan, L.X. He, and Z.Y. Wang Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients J Int Med Res 38 2010 977 986
31. F. Sun, Y. Chen, Y. Xiang, and S. Zhan Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis Int J Tuberc Lung Dis 12 2008 994 1002
32. S.W. Lee, L.S. Chung, H.H. Huang, T.Y. Chuang, Y.H. Liou, and L.S. Wu NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis Int J Tuberc Lung Dis 14 2010 622 626
33. L.A. Howard, A.L. Micu, E.M. Sellers, and R.F. Tyndale Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver J Pharmacol Exp Ther 299 2001 542 550
34. N.L. Benowitz, M. Peng, and P. Jacob III Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism Clin Pharmacol Ther 74 2003 468 474
35. V. Pachauri, and S.J. Flora Effect of nicotine pretreatment on arsenic-induced oxidative stress in male Wistar rats Hum Exp Toxicol 32 2013 972 982
36. J. Yue, R. Peng, J. Chen, Y. Liu, and G. Dong Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats Pharmacol Res 59 2009 112 119
37. J. Park, J.W. Kang, and S.M. Lee Activation of the cholinergic anti-inflammatory pathway by nicotine attenuates hepatic ischemia/reperfusion injury via heme oxygenase-1 induction Eur J Pharmacol 707 2013 61 70
38. R. Freedman Alpha7-nicotinic acetylcholine receptor agonists for cognitive enhancement in Schizophrenia Annu Rev Med 65 2014 245 261
39. J. Voutsinas, L.R. Wilkens, A. Franke, T.M. Vogt, L.A. Yokochi, R. Decker, and L. Le Marchand Heterocyclic amine intake, smoking, cytochrome P450 1A2 and N-acetylation phenotypes, and risk of colorectal adenoma in a multiethnic population Gut 62 2013 416 422